Powder vials
Store at −20 °C (−4 °F) in dry, dark conditions and keep them in the original packaging.

Most people use 1 to 2 mg of tesamorelin a day, in the morning on an empty stomach. With a 10 mg vial mixed with 2 mL of water, 2 mg is 40 units on a U-100 syringe. Most people run it 5 days on and 2 days off for 12 weeks.
The amounts in this chart come from online communities. The vial label shows the total peptide in milligrams (mg). The Amount column shows a portion of that total in micrograms (mcg). The syringe mark shows how much liquid corresponds to that amount.
Syringe marks below are based on a 10 mg vial with 2 mL of water added. Change vial size or water in the calculator
| Reported | Amount | Volume | Syringe mark (U-100) | Draws per vial |
|---|
Convert your vial to mcg, because 1 mg is the same as 1,000 mcg.
Divide by your water to see how much is in 1 mL.
Find what one unit holds. A U-100 syringe has 100 units in 1 mL.
Divide your amount by what one unit holds.
Most people take it once a day, 5 days on and 2 days off. The trials used it every day without breaks.
Most people take it in the morning on an empty stomach. Food, especially carbs and fat, can blunt the growth hormone pulse.
Under the skin of the belly, the same as the trials used.
Most people run it for 12 weeks, then take 4 to 6 weeks off. Many rotate it with CJC-1295 and Ipamorelin.
Follow one step at a time. The steps use the water amount from your calculator.
Find the mg printed on your vial and enter it in the calculator. Let a frozen vial reach room temperature first.
Clean the top of the peptide vial and the water vial with an alcohol swab. Let them dry.
Draw bacteriostatic water with a sterile syringe.
Let the water run down the inside wall of the vial. This helps prevent foaming.
Roll the vial until the powder fully dissolves. Do not shake it hard.
Write today's date on the vial and refrigerate it at 2–8 °C (35.6–46.4 °F), away from light.

Pick how many weeks you will run it and how many shots you take each week. The list below shows everything you need.
Store at −20 °C (−4 °F) in dry, dark conditions and keep them in the original packaging.
Keep them refrigerated and away from light. How long a mixed vial lasts depends on the product, so check its stability data.
Tesamorelin is a lab-made copy of GHRH, the hormone your brain uses to tell your pituitary gland to release growth hormone. Your body makes only a tiny amount of GHRH, and an enzyme in your blood called DPP-IV cuts natural GHRH apart within minutes. Tesamorelin has a cap on one end that protects it from that enzyme.
It is the only growth hormone peptide on this list with FDA approval, granted in 2010 for excess abdominal fat in adults with HIV-associated lipodystrophy. It works one step upstream of injected growth hormone, so your pituitary still decides when the pulses fire and how big they are.
This is where the trial evidence is strongest. Tesamorelin was approved to reduce exactly this fat, measured by CT scan rather than by the scale or the mirror.
In five randomized trials, visceral fat came down while lean body mass went up at the same time. Most compounds studied for body composition move one of those numbers, not both.
Trunk fat, waist size, and liver fat all came down alongside visceral fat in the pooled trial data.
Like the other growth hormone peptides, people report deeper sleep and better recovery.
Growth hormone tilts the body toward burning fat instead of muscle protein during a calorie deficit. People losing weight fast use it for that reason, though no study has tested this directly.
Most people notice deeper sleep in the first week or two. The body composition changes in the trials were measured at 26 and 52 weeks, so this one rewards patience.
Pick a topic to see what has been studied.
A 2026 meta-analysis pooled five randomized controlled trials of tesamorelin against placebo. Visceral fat came down by 27.71 square centimeters compared with placebo, measured by CT scan. Trunk fat, waist circumference, and liver fat also came down.
The same 2026 meta-analysis reported a modest increase in lean body mass alongside the drop in visceral fat. Lean body mass includes water and other tissue, not just muscle, and no trial has tested tesamorelin for muscle building in healthy trained people.
Scientists hunted for GHRH for decades without finding it, because the body makes so little. A patient turned up with a pancreatic tumor producing it in bulk, and Roger Guillemin's team at the Salk Institute isolated it and published the structure in Science in 1982. Tesamorelin is that same molecule with a guard on its nose.
This is the finding worth reading twice. The FDA label reports that 5% of treated patients in the registration trials reached an A1C of 6.5% or higher, compared with 1% on placebo. Most people did not move on blood sugar, and a real minority did. Anyone running this should get an A1C and a fasting glucose before starting and again a few months in.
There are two tesamorelin doses in circulation and they belong to two different products. The original EGRIFTA SV was studied and approved at 2 mg once daily, which is what both phase 3 trials used. The 2025 EGRIFTA WR formula uses 1.28 mg once daily, and the FDA label states the two are not interchangeable.
No published study has tested tesamorelin alongside a GLP-1 medication. A 2026 study of 7,965 people on GLP-1s found that the strongest predictor of heavy lean mass loss was reduced exercise tolerance, not age or starting weight. The mechanism makes tesamorelin a reasonable question for that group, but the combination has not been studied in humans.

Quality varies a lot between sellers. I have been around research peptides for 10 years, and BioEdge is the supplier I send my readers to. Here is why.
The Peptide Report has a business relationship with BioEdge Research Labs. BioEdge sells this product for laboratory research only. BioEdge shipping policy
These are the stacks people use most with tesamorelin, and what each one adds.
| Stack | Ingredients | Why people stack them |
|---|---|---|
| Tesamorelin + CJC-1295 / Ipamorelin2 vials | IngredientsTesamorelin at 1 to 2 mg, 5 days on and 2 days off. CJC-1295 / Ipamorelin at 250 mcg each in the next cycle | Growth hormone rotationTesamorelin is the stronger of the two, with the most human research behind it. CJC-1295 with Ipamorelin is the lighter pair. Many people run one for 12 weeks, take 4 weeks off, then run the other. Rotating keeps the body responding. |
| Tesamorelin + BPC-1572 vials | IngredientsTesamorelin at 1 to 2 mg daily. BPC-157 at 400 mcg daily | Recovery and repairYour body does most of its repair during deep sleep, and growth hormone peptides deepen that sleep. People add BPC-157 when they are working through an injury at the same time. See the BPC-157 dosage guide. |
Pick a tool and try it. Each one uses the numbers from your calculator.
Use the same four steps. Once you can solve these, you can work out the units for any vial you ever pick up.
Your score: 0 correct.
Each line on the syringe is a unit of liquid. A unit measures volume, so the amount of peptide in it depends on your mix.
Tap the syringe or move the slider. The numbers use the vial you entered above. Read the line at the top edge of the plunger.
More water makes the mix weaker, so the same amount takes up more units. The amount of peptide in the vial stays the same.
A draw under 5 units is harder to read accurately. Tap a row to use that water amount.
The original EGRIFTA SV formula was studied and approved at 2 mg once daily by subcutaneous injection. The newer EGRIFTA WR formula uses 1.28 mg once daily. The FDA label states the two products are not interchangeable, so a single dose quoted with no formula attached to it has not been checked.
With a 10 mg vial and 2 mL of water, 2 mg is 40 units on a U-100 syringe. Use the calculator if your mix is different.
Tesamorelin is FDA approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. It is not approved for general weight loss, for muscle preservation, or for use alongside GLP-1 medications.
In a 2026 meta-analysis of five randomized controlled trials, tesamorelin reduced visceral fat by 27.71 square centimeters compared with placebo, measured by CT scan. Trunk fat, waist circumference, and liver fat also came down.
The 2026 meta-analysis reported a modest increase in lean body mass alongside the reduction in visceral fat. Lean body mass includes muscle along with water and other tissue, so it is not a direct measure of muscle alone. No trial has tested tesamorelin for muscle building in healthy trained people.
No published study has tested tesamorelin alongside a GLP-1 medication. The mechanism makes it a reasonable question, since growth hormone spares protein during a caloric deficit, but that combination has not been studied in humans.
The FDA label reports that 5% of treated patients in the registration trials reached an A1C of 6.5% or higher, compared with 1% on placebo. IGF-1 elevation, swelling, joint aches, and injection site reactions are also reported. Long-term cardiovascular safety has not been established.
The research used daily continuous administration rather than short cycles, with people staying on it through 52 weeks. Most people running it outside a trial use 5 days on and 2 days off for 12 weeks, then take 4 to 6 weeks off.
Injected growth hormone replaces the hormone directly and overrides your own release pattern. Tesamorelin acts one step upstream on the pituitary, so your body still controls when the pulses fire and how large they are.
Most charts assume one vial size and one water amount. If your mix is different, every unit number changes, so run your own numbers.
Instant e-Book Download